Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radiation Seed Implants for Breast Cancer

By HospiMedica staff writers
Posted on 22 Jan 2006
Canadian researchers are evaluating the effectiveness of permanent radiation seed implants following lumpectomy as an alternative to whole or partial breast irradiation for early-stage breast cancer patients, according to a new study. More...
This kind of radiation would decrease treatment time for certain patients from several weeks to one day.

For early stage breast cancer, women frequently undergo a lumpectomy to remove the tumor followed by radiation therapy to destroy any cancer cells that may remain. Most women undergo external beam radiation, which is given daily, Monday through Friday, for six to eight weeks.

Clinicians have been exploring ways to decrease the treatment times. One technique used by a growing number of radiation oncologists involves the use of temporary radiation implants. These radiation sources are delivered through a catheter into the breast, typically twice a day for one week.

In this study, published in the January 1, 2006, issue of the International Journal of Radiation Oncology*Biology*Physics, clinicians wanted to see if it was possible to use permanent implants, similar to what many men receive to treat prostate cancer, to fight the cancer with only one treatment. These implants, approximately the size of a grain of rice, would not be removed daily, which is the case with the temporary implants. Instead, the radioactive seeds would deliver radiation to the breast region for a number of weeks until they were no longer radioactive. The advantage over the temporary implants is that the patient only has to undergo one surgical procedure to receive the radiation, versus 10 treatments over one week for temporary implants.

The current standard of treating lumpectomy followed by external beam radiation therapy has been shown to keep the cancer from recurring; however, 38% of women develop considerable toxicity, which can compromise their quality of life. According to early findings of the study, which started in May 2004, 44 patients have been effectively treated with the permanent implants. Up to now, none have evidence of their cancer returning and acute skin irritation is six times less frequent when compared to external beam radiation.

"The main motivation was to see if we could reduce the burden of treatment for women suffering from early-stage breast cancer,” stated Jean-Philippe Pignol, M.D., Ph.D., lead author of the study and radiation oncologist at Sunnybrook and Women's College Health Sciences Centre (Toronto, Ontario, Canada).



Related Links:
Sunnybrook and Women's College Health Sciences Centre

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.